Novo Nordisk increases commitment to stem cell-based therapies
Novo Nordisk today announced an increased commitment to stem cell-based therapies and an expansion of the focus on type 1 diabetes into other serious chronic diseases. This has been made possible through an exclusive collaboration with the University of California San Francisco (UCSF) in which a first milestone in the development of human embryonic stem cell lines has been reached.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news
More News: Diabetes | Diabetes Type 1 | Endocrinology | Pharmaceuticals | Stem Cell Therapy | Stem Cells